Compare Stocks: BMRA, LUCY, NXGL, and CUPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRA Biomerica	$1.63 +1.2%	$1.76	$1.45 ▼ $4.60	$4.98M	0.35	6,514 shs	9,531 shs
CUPR Cuprina Holdings (Cayman)	$3.04 -8.4%	$4.10	$1.76 ▼ $76.00	$3.06M	-0.35	56,557 shs	21,803 shs
LUCY Innovative Eyewear	$0.70 -3.2%	$0.84	$0.65 ▼ $2.27	$4.61M	2.72	361,460 shs	92,677 shs
NXGL NexGel	$0.36 -4.6%	$0.50	$0.33 ▼ $2.89	$3.51M	0.78	84,563 shs	78,585 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRA Biomerica	0.00%	+10.40%	-2.66%	-27.85%	-47.11%
CUPR Cuprina Holdings (Cayman)	0.00%	+13.70%	-33.20%	+53.42%	+331,999,900.00%
LUCY Innovative Eyewear	0.00%	+3.33%	-33.32%	-29.40%	-63.26%
NXGL NexGel	0.00%	-8.46%	-26.63%	-37.19%	-85.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRA Biomerica	$1.63 +1.2%	$1.76	$1.45 ▼ $4.60	$4.98M	0.35	6,514 shs	9,531 shs
CUPR Cuprina Holdings (Cayman)	$3.04 -8.4%	$4.10	$1.76 ▼ $76.00	$3.06M	-0.35	56,557 shs	21,803 shs
LUCY Innovative Eyewear	$0.70 -3.2%	$0.84	$0.65 ▼ $2.27	$4.61M	2.72	361,460 shs	92,677 shs
NXGL NexGel	$0.36 -4.6%	$0.50	$0.33 ▼ $2.89	$3.51M	0.78	84,563 shs	78,585 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRA Biomerica	0.00%	+10.40%	-2.66%	-27.85%	-47.11%
CUPR Cuprina Holdings (Cayman)	0.00%	+13.70%	-33.20%	+53.42%	+331,999,900.00%
LUCY Innovative Eyewear	0.00%	+3.33%	-33.32%	-29.40%	-63.26%
NXGL NexGel	0.00%	-8.46%	-26.63%	-37.19%	-85.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRA Biomerica	1.00	Sell	$9.00	452.15% Upside
CUPR Cuprina Holdings (Cayman)	1.00	Sell	N/A	N/A
LUCY Innovative Eyewear	1.50	Reduce	N/A	N/A
NXGL NexGel	2.00	Hold	$2.00	451.88% Upside

Current Analyst Ratings Breakdown

Latest BMRA, LUCY, NXGL, and CUPR Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/17/2026	CUPR Cuprina Holdings (Cayman)	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	LUCY Innovative Eyewear	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	NXGL NexGel	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/5/2026	BMRA Biomerica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/3/2026	LUCY Innovative Eyewear	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/21/2026	BMRA Biomerica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRA Biomerica	$5.31M	0.95	N/A	N/A	$1.61 per share	1.01
CUPR Cuprina Holdings (Cayman)	$40K	69.92	N/A	N/A	$1.50 per share	2.03
LUCY Innovative Eyewear	$2.66M	1.68	N/A	N/A	$1.69 per share	0.41
NXGL NexGel	$11.42M	0.29	N/A	N/A	$0.60 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRA Biomerica	-$4.97M	-$0.89	N/A	N/A	N/A	-96.49%	-98.14%	-70.42%	8/27/2026 (Estimated)
CUPR Cuprina Holdings (Cayman)	-$3.63M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUCY Innovative Eyewear	-$7.59M	-$1.69	N/A	N/A	N/A	-272.42%	-83.37%	-76.02%	8/13/2026 (Estimated)
NXGL NexGel	-$3M	-$0.40	N/A	N/A	N/A	-28.54%	-64.29%	-29.64%	8/11/2026 (Estimated)

Latest BMRA, LUCY, NXGL, and CUPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2026	N/A	BMRA Biomerica	-$0.88	N/A	N/A	N/A	$2.22 million	N/A
8/13/2026	Q2 2026	LUCY Innovative Eyewear	-$0.37	N/A	N/A	N/A	$0.90 million	N/A
8/11/2026	Q2 2026	NXGL NexGel	-$0.12	N/A	N/A	N/A	$4.32 million	N/A
5/14/2026	Q1 2026	LUCY Innovative Eyewear	-$0.47	-$0.37	+$0.10	-$0.37	$0.70 million	$0.77 million
5/14/2026	Q1 2026	NXGL NexGel	-$0.07	-$0.11	-$0.04	-$0.11	$3.91 million	$2.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRA Biomerica	N/A	N/A	N/A	N/A	N/A
CUPR Cuprina Holdings (Cayman)	N/A	N/A	N/A	N/A	N/A
LUCY Innovative Eyewear	N/A	N/A	N/A	N/A	N/A
NXGL NexGel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRA Biomerica	N/A	2.64	1.59
CUPR Cuprina Holdings (Cayman)	0.07	2.35	2.35
LUCY Innovative Eyewear	N/A	8.02	6.09
NXGL NexGel	0.45	1.70	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRA Biomerica	22.28%
CUPR Cuprina Holdings (Cayman)	N/A
LUCY Innovative Eyewear	0.96%
NXGL NexGel	2.21%

Insider Ownership

Company	Insider Ownership
BMRA Biomerica	18.00%
CUPR Cuprina Holdings (Cayman)	N/A
LUCY Innovative Eyewear	1.66%
NXGL NexGel	23.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRA Biomerica	60	3.09 million	2.53 million	No Data
CUPR Cuprina Holdings (Cayman)	14	920,000	N/A	N/A
LUCY Innovative Eyewear	9	6.40 million	6.30 million	Not Optionable
NXGL NexGel	10	9.23 million	7.07 million	Not Optionable

BMRA, LUCY, NXGL, and CUPR Headlines

Recent News About These Companies

NexGel (NXGL) Expected to Release Quarterly Earnings on Tuesday

August 9 at 3:56 AM | americanbankingnews.com

NexGel announces audit committee chair board resignation

July 2, 2026 | tipranks.com

NexGel, Inc Common Stock (NXGL)

June 17, 2026 | nasdaq.com

NexGel Updates Investor Presentation Under Regulation FD Disclosure

June 17, 2026 | tipranks.com

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

June 5, 2026 | markets.businessinsider.com

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

June 4, 2026 | globenewswire.com

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a ...

May 19, 2026 | finance.yahoo.com

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

May 19, 2026 | globenewswire.com

Nexgel (NXGL) Q1 2026 Earnings Transcript

May 16, 2026 | theglobeandmail.com

NexGel Raises Insider-Funded Convertible Notes to Bolster Liquidity

May 15, 2026 | tipranks.com

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

May 15, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: NexGel Inc (NXGL) and Phathom Pharmaceuticals (PHAT)

May 15, 2026 | theglobeandmail.com

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

May 14, 2026 | markets.businessinsider.com

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

May 12, 2026 | globenewswire.com

NEXGEL Secures Strategic Financing and Regenerative Portfolio License

April 24, 2026 | theglobeandmail.com

NexGel Receives Nasdaq Deficiency Notice Over Bid Price

April 24, 2026 | tipranks.com

NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript

April 21, 2026 | seekingalpha.com

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

April 17, 2026 | globenewswire.com

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

April 15, 2026 | globenewswire.com

NEXGEL reschedules shareholder call, revises financing plan

April 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, LUCY, NXGL, and CUPR Company Descriptions

Biomerica NASDAQ:BMRA

$1.63 +0.02 (+1.24%)

As of 04:00 PM Eastern

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Cuprina Holdings (Cayman) NASDAQ:CUPR

$3.04 -0.28 (-8.43%)

As of 04:00 PM Eastern

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future. As of June 30, 2024, we manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement. In addition to our currently commercialized MEDIFLY products, we have two lines of chronic wound care products in our pipeline. Such lines of pipeline chronic wound care products include: . Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus); and . Products utilizing medical leeches for wound treatment. We currently expect development of such products to take place over the course of 2025 and 2026 and to become commercially available subject to regulatory approval. However, we may not be able to successfully develop the aforementioned pipeline products on the timeline currently envisioned, or at all, and even if we do, these products may not receive the necessary regulatory approvals from the authorities in the intended markets where we plan to introduce them. We believe what sets us apart is our focus on developing functionally specific chronic wound care products designed to address the major stages of wound healing process, from chronic to closure. Our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline, are poised to benefit from escalating global market demand. This demand is primarily fueled by the demographic shift towards an aging population and the concurrent rise in comorbidities such as diabetes, obesity, cardiovascular ailments, and peripheral vascular diseases. We either self-develop our chronic wound care products or co-develop them through technology licensing agreements or research collaboration with a renowned research university. In June 2022, we were granted an exclusive license from NTUitive Pte. Ltd., a wholly owned subsidiary of Nanyang Technological University, to develop and commercialize a range of chronic wound care products using collagen derived from bullfrog skin. In addition, in August 2022, we entered into an industry research collaboration agreement with Nanyang Technological University, or, together with its subsidiaries, NTU, pursuant to which both parties agreed to jointly undertake a research project regarding the development and validation of bullfrog skin waste to generate collagen-based wound care products. We have been selling our MEDIFLY products primarily in Singapore since February 2020. In March 2023, our MEDIFLY products became commercially available in Hong Kong. Looking ahead, we have strategic plans in place for 2025 and 2026 to expand our sales and establish physical operations in several key regions, including the Middle East (in particular, the member states of the Gulf Cooperation Council, or GCC), and mainland China. These expansion initiatives will further enable us to cater to the growing demand for our products in these promising markets, cementing our position as a trusted player in the field of chronic wound care and treatment. For our cosmeceuticals business, we introduced three products in 2023, including a hydrating balm product, a muscle energy cream and a pain relief muscle patch. For our currently commercialized cosmeceutical products, we have commissioned original equipment manufacturers of skincare products to develop the formulation and manufacture the substantially finished and finished products. In addition, we plan to explore the possibility of developing a range of potential cosmeceutical product candidates incorporating bullfrog collagen with a view to making them commercially available between 2025 and 2028, subject to the progress of the relevant R&D work. We offer our chronic wound care products to both public and private hospitals and clinics, where patients can obtain them through prescription from a physician. Our customers primarily include major public and private hospitals and clinics in Singapore. Our commercialized cosmeceutical products can be purchased directly by individual customers through a variety of channels, including retailers and gyms in Singapore and other countries such as Malaysia and Australia, as well as online shopping platforms such as Shopee. Our commitment to quality is demonstrated by our attainment of ISO 13485:2016 standards for Quality Management Systems and Manufacturing Processes and Controls for our manufacturing facility located in Singapore in 2020. We are working towards obtaining compliance with 21 CFR Part 820, an integral component of the Current Good Manufacturing Practice, or CGMP, regulations, to secure FDA 510(k) clearance for our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline. Our principal executive office is in Singapore.

Innovative Eyewear NASDAQ:LUCY

$0.70 -0.02 (-3.21%)

As of 04:00 PM Eastern

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.

NexGel NASDAQ:NXGL

$0.36 -0.02 (-4.63%)

As of 04:00 PM Eastern

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRA, LUCY, NXGL, and CUPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRA, LUCY, NXGL, and CUPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRA, LUCY, NXGL, and CUPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, LUCY, NXGL, and CUPR Company Descriptions

Biomerica NASDAQ:BMRA

Cuprina Holdings (Cayman) NASDAQ:CUPR

Innovative Eyewear NASDAQ:LUCY

NexGel NASDAQ:NXGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRA, LUCY, NXGL, and CUPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRA, LUCY, NXGL, and CUPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRA, LUCY, NXGL, and CUPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, LUCY, NXGL, and CUPR Company Descriptions

Biomerica NASDAQ:BMRA

Cuprina Holdings (Cayman) NASDAQ:CUPR

Innovative Eyewear NASDAQ:LUCY

NexGel NASDAQ:NXGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools